retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 Beyond GLP-1: Retatrutide's triple-agonist mechanism (GLP-1, GIP, glucagon) is redefining metabolic health. data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing Retatrutide: A Triple Agonist Shaping

Description

The problem is that patients don't know the difference, and they'll often be looking for the most accessible route to get to the medication that they want

A thorough review of the studies that led to tirzepatides approval allows for comparisons between tirzepatide and GLP-1 RAs

doi: 10.1002/path.5056

J Taibah Univ Med Sci

It summarizes categories that typically influence long-term satisfaction, including user experience, bonus structure, and support availability across devices